EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieMultizentrische Studie

Effectiveness and Safety of Varying Doses of Linezolid With Bedaquiline and Pretomanid in Treatment of Drug-Resistant Pulmonary Tuberculosis: Open-Label, Randomized Clinical Trial

Chandrasekaran Padmapriyadarsini iD, Vikas S Oswal, Chetankumar D Jain, Muthu Vijayalakshmi Mariappan, Neeta Singla, Santosh Kumar, Bella Devaleenal Daniel, Jigna D Dave, Parul Vadgama, Balaji Ramraj, Surya Kant, Anuj K Bhatnagar und 19 weitere

Clinical Infectious Diseases · 2024

DOI: 10.1093/cid/ciae388 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift Clinical Infectious Diseases, 2024. Verfasst von Chandrasekaran Padmapriyadarsini und 30 weiteren Autor:innen. Beteiligte Einrichtung: Department of Clinical Research, ICMR-National Institute for Research in Tuberculosis, Chennai, India. Hauptthemen laut MEDLINE: Linezolid, Diarylquinolines, Antitubercular Agents, Tuberculosis, Pulmonary. Die Arbeit wurde bisher 26-mal zitiert (Crossref) und nennt 26 Literaturangaben. Gefördert von: World Health Organization, United States Agency for International Development, US Agency for International Development.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Treatment of drug-resistant tuberculosis with bedaquiline-pretomanid-linezolid regimen has demonstrated good treatment efficacy. Given linezolid's toxicity profile, prudence suggests reconsidering its dose and duration. We determined the effectiveness and safety of structured dose reduction of linezolid with bedaquiline and pretomanid in adults with pre–extensively drug-resistant (pre-XDR) or treatment-intolerant/nonresponsive multidrug-resistant (MDRTI/NR) pulmonary tuberculosis.

Method

Adults with pre-XDR or MDRTI/NR pulmonary tuberculosis were enrolled in a multicenter, parallel-group, randomized clinical trial in India. Patients were randomized to 26 weeks of bedaquiline, pretomanid, and daily linezolid, at 600 mg for 26 weeks (arm 1); 600 mg for 9 weeks followed by 300 mg for 17 weeks (arm 2); or 600 mg for 13 weeks followed by 300 mg for 13 weeks (arm 3). Study end points included sustained cure, bacteriological failure, toxicity, and death.

Results

Of 403 patients enrolled, 255 (63%) were <30 years old, 273 (68%) had prior tuberculosis episodes, and 238 (59%) were malnourished. At the end of treatment, after excluding those with negative baseline cultures, cure was seen in 120 (93%), 117 (94%), and 115 (93%) in arms 1, 2, and 3 respectively. Myelosuppression seen in 85 patients each in arms 1 and 2 and 77 patients in arm 3, not significantly different. Peripheral neuropathy was noticed in 66 patients (30, 17, and 19 in arms 1, 2, and 3) at 10–26 weeks (P = .02). The linezolid dose was reduced because of toxicity in 13, 2, and 4 patients in arms 1, 2, and 3, respectively.

Conclusions

In adults with pre-XDR or MDRTI/NR pulmonary tuberculosis, structured linezolid dose reduction to 300 mg/d is as effective as the standard 600-mg dose but with fewer cases of peripheral neuropathy when given with bedaquiline and pretomanid. Clinical Trials Registration Clinical Trial Registry of India (CTRI/2021/03/032189)

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

LinezolidDiarylquinolinesAntitubercular AgentsTuberculosis, PulmonaryTuberculosis, Multidrug-ResistantHumansFemaleMaleAdultMiddle AgedTreatment OutcomeYoung AdultIndiaDrug Therapy, CombinationOxazolidinonesAdolescentNitroimidazoles

Stichwörter der Autor:innen

drug-related toxicitydrug-resistant tuberculosislinezolidpretomanidstructured dose reduction

Substanzen

LinezolidbedaquilineDiarylquinolinesAntitubercular AgentspretomanidOxazolidinonesNitroimidazoles

Autor:innen und Institutionen

  • Department of Clinical Research, ICMR-National Institute for Research in Tuberculosis, Chennai, India.
  • DRTB Site, Pandit Malviya Shatabdi Centenary Hospital, Mumbai, India.
  • DRTB DOTS Plus Site, Sarvodaya Charitable Trust Hospital, Mumbai, India.
  • Department of Epidemiology and Public Health, National Institute for Tuberculosis and Respiratory Diseases, New Delhi, India.
  • Department of Pulmonary Medicine, Sarojini Naidu Medical College, Agra, India.
  • Department of Respiratory Medicine, Government Medical College, Bhavnagar, India.

ORCID-Profile: Chandrasekaran Padmapriyadarsini

Förderung

  • World Health Organization
  • United States Agency for International Development
  • US Agency for International Development

Zitieren

APA

Padmapriyadarsini, C., Oswal, V. S., Jain, C. D., Mariappan, M. V., Singla, N., Kumar, S., Daniel, B. D., Dave, J. D., Vadgama, P., Ramraj, B., Kant, S., Bhatnagar, A. K., Shanmugam, S., Paul, D., Bharathi, J., Palav, M., Shah, N. V., Santhanakrishnan, R., Dewan, R. K., …, & modified BPaL (mBPaL) Study Team (2024). Effectiveness and Safety of Varying Doses of Linezolid With Bedaquiline and Pretomanid in Treatment of Drug-Resistant Pulmonary Tuberculosis: Open-Label, Randomized Clinical Trial. Clinical Infectious Diseases. https://doi.org/10.1093/cid/ciae388

Vancouver

Padmapriyadarsini C, Oswal VS, Jain CD, Mariappan MV, Singla N, Kumar S, et al. Effectiveness and Safety of Varying Doses of Linezolid With Bedaquiline and Pretomanid in Treatment of Drug-Resistant Pulmonary Tuberculosis: Open-Label, Randomized Clinical Trial. Clinical Infectious Diseases. 2024. doi:10.1093/cid/ciae388

BibTeX
@article{Padmapriyadarsini2024,
  author = {Padmapriyadarsini, Chandrasekaran and Oswal, Vikas S and Jain, Chetankumar D and Mariappan, Muthu Vijayalakshmi and Singla, Neeta and Kumar, Santosh and Daniel, Bella Devaleenal and Dave, Jigna D and Vadgama, Parul and Ramraj, Balaji and Kant, Surya and Bhatnagar, Anuj K and Shanmugam, Sivakumar and Paul, Dhamodharan and Bharathi, Jeyadeepa and Palav, Manasi and Shah, Neha V and Santhanakrishnan, Rameshkumar and Dewan, Ravindra K and Shekh, Nadim and Rathinam, Prabhakaran and Sisara, Arvind B and Mankar, Shubhangi Dhakulkar and Bajpai, Jyoti and Mittal, Upasana and Chauhan, Sandeep and Kumar, Ravinder and Parmar, Mallik and Mattoo, Sanjay K and Jaju, Jyoti and modified BPaL (mBPaL) Study Team, modified BPaL (mBPaL) Study Team},
  title = {Effectiveness and Safety of Varying Doses of Linezolid With Bedaquiline and Pretomanid in Treatment of Drug-Resistant Pulmonary Tuberculosis: Open-Label, Randomized Clinical Trial},
  journal = {Clinical Infectious Diseases},
  year = {2024},
  doi = {10.1093/cid/ciae388}
}
Kostenlos starten →